ALVO: Executing Biosimilar Pipeline And 2026 Revenue Plan Will Unlock Upside

Analysts have reset their view on Alvotech, trimming the average price target from about $22.17 to $14.00 as they factor in updated assumptions for growth, profitability and a higher future P/E, in line with recent target cuts from Deutsche Bank, Barclays and UBS.

Analyst Commentary

Recent Street research around the reset in the average price target to about $14.00 centers on how quickly Alvotech can execute on its pipeline and translate that into sustainable profitability, as well as what P/E multiple is appropriate given current visibility.

Bullish Takeaways

Bullish analysts view the updated price targets as a recalibration rather than a rejection of the long term story, arguing that the new levels better reflect current execution timelines and risk.
Supportive commentary highlights potential for earnings leverage if the company can align costs with revenue growth, which could justify a higher future P/E than what is implied by the latest target cuts.
Some see the clustered revisions as reducing uncertainty around expectations, giving investors a clearer entry framework on revenue, margin and valuation assumptions.
There is an underlying view that if management hits key operational milestones, the gap between the current share price and the revised targets could still offer meaningful upside, even after the cuts.

Bearish Takeaways

Bearish analysts focus on execution risk, suggesting that prior expectations for growth and profitability were too aggressive given recent developments, which led to the reduced price targets.
Concerns are tied to visibility on timing of revenue contributions from key assets, with some seeing limited room for error before further model adjustments would be needed.
The reliance on a higher future P/E to support valuation is flagged as a risk, especially if earnings delivery or market conditions do not fully support that level of multiples.
There is caution that repeated target trims within a short window may signal that forecasts are still being recalibrated, which can keep some investors on the sidelines until the earnings trajectory is clearer.

What's in the News

Reaffirmed 2026 earnings guidance, with Alvotech indicating an expectation for total revenues in the range of US$650 million to US$700 million, supported by a focus on cash flow and margin expansion through sales growth and operational efficiencies (Corporate guidance).
Reported positive top line results from a pharmacokinetic study for AVT80, a biosimilar candidate to Entyvio, with the trial meeting all primary endpoints for pharmacokinetic similarity, safety, tolerability and immunogenicity in healthy adults, while emphasizing that biosimilarity has not been established by regulators (Product related announcement).
Entered supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada, Australia and New Zealand. Under these agreements, Sandoz will handle regulatory submissions and commercialization, and Alvotech will focus on development, clinical work and manufacturing under exclusive supply arrangements (Client announcement).
Reached a licensing and settlement agreement with Regeneron and Bayer covering worldwide patent disputes around Alvotech’s aflibercept biosimilar. The agreement secures defined market entry dates across the UK, Canada, Japan, the European Economic Area and other regions, while keeping financial terms confidential (Client announcement).
Announced senior leadership changes, with founder Róbert Wessman set to move from CEO to full time Executive Chairman at the end of Q1 2026 and Lisa Graver appointed as the next CEO, following a transition period. The company also reported that Alvotech has been removed from the OMX Nordic All Share Index and has arranged a US$100 million senior term loan facility maturing in 2027 at a 12.50% interest rate (Executive changes, index change, financing).

Valuation Changes

Fair Value: reset from $22.17 to $14.00, a sizeable reduction that tightens the implied upside versus prior assumptions.
Discount Rate: moved up from 7.86% to 9.13%, indicating a higher required return and a heavier weighting on risk in the models.
Revenue Growth: trimmed from 31.93% to 18.52%, reflecting more conservative expectations for how quickly dollar revenue may build over the forecast period.
Net Profit Margin: adjusted from 24.47% to 19.33%, pointing to a more measured view on future earnings efficiency from each dollar of sales.
Future P/E: lifted from 25.38x to 36.67x, signaling that a higher earnings multiple is being used to support the revised equity value despite the lower growth and margin inputs.

16 views

Key Takeaways

Accelerating global biosimilar adoption and strategic partnerships expand Alvotech's market reach, boosting future revenue stability and margin potential.
Vertical integration and acquisitions improve operational efficiency and resilience, supporting sustainable earnings growth amid industry-wide cost pressures.
Reliance on unpredictable milestone payments, intense price competition, high fixed costs, heavy partner concentration, and regulatory risks threaten revenue stability, margin health, and long-term profitability.

Catalysts

About Alvotech

Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.What are the underlying business or industry changes driving this perspective?

Alvotech's expanding global rollout and market share gains for its leading biosimilars, especially Humira and STELARA, signal continued growth as payers worldwide accelerate the shift to biosimilars-directly supporting future revenue and cash flow growth.
Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off-patent, potentially driving a step-change in topline revenue once approvals are secured.
Strengthened strategic partnerships (e.g., Advanz Pharma, Teva, Dr. Reddy's) and expanding distribution footprint enable Alvotech to rapidly access new regions and patient pools as governments seek more cost-effective treatment options, likely enhancing future revenue predictability and operating margins.
Investments in vertical integration and acquisitions (Xbrane R&D, Ivers-Lee) improve operational control and cost efficiencies, expected to enhance gross margin resilience and support sustainable earnings growth amid industry-wide margin pressures.
Sustained global trends of aging populations and rising chronic diseases are structurally increasing demand for biologic therapies, expanding the biosimilar addressable market and underpinning long-term revenue visibility and upside for Alvotech.

Alvotech Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Alvotech's revenue will grow by 18.5% annually over the next 3 years.
Analysts assume that profit margins will increase from 4.7% today to 19.3% in 3 years time.
Analysts expect earnings to reach $189.6 million (and earnings per share of $0.65) by about March 2029, up from $27.9 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $318.1 million in earnings, and the most bearish expecting $86.4 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 36.7x on those 2029 earnings, down from 36.9x today. This future PE is greater than the current PE for the US Biotechs industry at 14.8x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.13%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Alvotech's guidance and revenue recognition are highly dependent on milestone payments tied to regulatory approvals, which are described as "lumpy" and unpredictable-delays in product approvals or shifts in regulatory timelines (such as FDA inspections or BsUFA date movements) could cause significant shortfalls in revenue, impacting both top-line and earnings volatility in the long term.
The biosimilar industry, especially in products like Humira and STELARA, faces intensifying price competition, with management highlighting "very competitive" pricing and unsustainably low offers from rivals-this pressure could lead to deteriorating net margins and erode profitability over the long term, especially as payer cost-containment becomes more aggressive globally.
Heavily increased R&D investment and recent acquisitions (e.g., Xbrane R&D and Ivers-Lee) add to Alvotech's fixed cost base at a time when cash flow, while improved, is still overshadowed by a high debt load ($1,139 million in debt versus $151 million in cash); if future launches or approvals are delayed or underperform, this could threaten liquidity, force dilutive equity issuance, or increase leverage, directly impacting shareholder value.
Alvotech's dependency on a small number of commercialization partners like Teva, Quallent and STADA for market access in key geographies introduces concentration risk-any unfavorable renegotiation, contract termination, or underperformance by these partners could lead to sudden revenue and market share declines, increasing volatility and reducing earnings visibility.
Regulatory scrutiny-particularly increased FDA and global inspections, or shifting standards for biosimilar approvals-remains a material risk; even "ordinary course" delays or raised quality hurdles could slow time-to-market for pipeline assets, limiting revenue growth and risking further lumpiness or outright misses on financial targets.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $14.0 for Alvotech based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $50.0, and the most bearish reporting a price target of just $4.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $980.5 million, earnings will come to $189.6 million, and it would be trading on a PE ratio of 36.7x, assuming you use a discount rate of 9.1%.
Given the current share price of $3.29, the analyst price target of $14.0 is 76.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Alvotech?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ALVO: Facility Improvements Will Drive Recovery Despite Recent Regulatory Setbacks